Affimed reorganises management team

Adi Hoess becomes chief executive

Affimed Therapeutics, a German therapeutic TandAb antibody company, has reorganised its management team under the leadership of Adi Hoess and Rolf Guenther.

Hoess, previously chief commercial officer, is now chief executive, while Guenther, previously chief executive, is now chief operating officer with a focus on advancing the pipeline through clinical trials.

"With a platform technology allowing development of multiple product candidates it is now time to adapt the organisation to the new needs,’ said Thomas Hecht, chairman of Affimed.

‘I am confident that under the leadership of Adi with his extensive business background in commercial operations and M&A strategies and with Rolf focusing on the clinical development of our core assets and overseeing the operations we have set up the company not only to build on its assets but also to prepare for its future.’

You may also like

Research & Development

Novel paths to treating rare diseases

Biotechnology is providing new pathways to treatments for many uncommon yet life-threatening diseases. Dr Sarah Houlton looks at some promising candidates
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Subscribe now